AAPL $273.68 +1.24% MSFT $413.27 -0.93% GOOGL $318.58 -1.35% AMZN $206.96 +0.47% NVDA $188.54 +1.43% TSLA $425.21 -0.83% META $670.72 -1.32% JPM $318.28 -1.32% V $328.17 +0.00% WMT $126.70 +0.95% AAPL $273.68 +1.24% MSFT $413.27 -0.93% GOOGL $318.58 -1.35% AMZN $206.96 +0.47% NVDA $188.54 +1.43% TSLA $425.21 -0.83% META $670.72 -1.32% JPM $318.28 -1.32% V $328.17 +0.00% WMT $126.70 +0.95%

NASDAQ: NKTR

Nektar Therapeutics

Healthcare • Biotechnology • www.nektar.com

$56.00 +$18.93 (+51.07%)

As of Feb 11, 12:57 AM UTC

Key Statistics

Market Cap $1.04B
P/E Ratio -8.02
Dividend Yield 0.00%
Volume 8,692,012
Avg Volume 882,666
52-Week High N/A
52-Week Low N/A

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Analyst Ratings

View All →
N/A Based on 0 analysts
Avg Price Target $121.00 (+116.1% upside)

NKTR News

View All →

FEATURED BY